We are excited to announce that the 2016 Harvard/Glenn Symposium on Aging will be held on Friday, June 17, 2016.
Each year, the Paul F. Glenn Laboratories host the Harvard Symposium on Aging with a mission to educate the wider research community about advancements in this fast-paced field and to stimulate collaborative research in this area. We have been fortunate to have many of the leaders in the aging field speak at the symposia.
We wish to acknowledge the generosity and vision of Paul F. Glenn, whose unwavering support for aging research for over 30 years has allowed it to grow into the cutting-edge field it is today. Today we are joined by Mark Collins, President of the Glenn Foundation for Medical Research and K. Leonard Judson, the Foundation’s Executive Vice President. Since the inception of the Paul F. Glenn labs at Harvard in 2005, the network of Paul F. Glenn Laboratories have grown into a consortium that includes Princeton University, Buck Institute, Massachusetts Institute of Technology, Salk Institute, Stanford University, and Albert Einstein College of Medicine.
The reasons for accelerating research into the molecular biology of aging are clear. First and foremost, the number of aged individuals in developed countries is growing rapidly, which is going to place an unprecedented burden on the families and the economies of those nations. Because chronic illness in the elderly is a major medical cost, enormous savings would be achieved if mortality and morbidity could be compressed within a shorter duration of time at the end of life. A study by the RAND Corporation concluded that advances in medicine arising from aging research would be one of the most cost-effective approaches to age-related disease. Advances in aging research have shown that it is possible to extend the healthy lifespan of laboratory animals through genetic and pharmacological means. Many leaders in the aging field predict that significant strides will be made in understanding how human health and lifespan are regulated, leading to novel medicines to forestall and treat diseases of aging such as diabetes, cancer, Alzheimer’s and heart disease.
Attendees come not only from the Harvard research community but from across the nation and from overseas for this one day event. On behalf of The Paul F. Glenn Laboratories and Harvard Medical School, we welcome you to the Harvard/Paul F. Glenn Symposium on Aging.
David Sinclair and Bruce Yankner
Co-Directors, The Paul F. Glenn Laboratories at Harvard Medical School